Cargando…
Dupilumab in the Treatment of Cheilitis in Atopic Dermatitis Patients
BACKGROUND/OBJECTIVES: The lip is a unique tissue type that acts as a “barrier” to the mouth and receives many external stimuli. It is also a common symptom in atopic dermatitis. Dupilumab was the first targeted biological drug approved for the treatment of moderate-to-severe atopic dermatitis (AD)....
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664921/ https://www.ncbi.nlm.nih.gov/pubmed/36387959 http://dx.doi.org/10.2147/CCID.S391944 |